Effects of Glucagon and Isoproterenol on Severity of Acute Myocardial Ischemic Injury

References

• Bache R. J., McHale P. A., Curry C. L., Alexander J. A., Greenfield J. C., Jr. Coronary and systemic hemodynamic effects of glucagon in the intact unanesthetized dog. J. appl. Physiol. 1970; 29: 769
   PubMed Web of Science ®Google Scholar
• Ballard F. B., Danforth W. H., Neagle S., Bing R. J. Myocardial metabolism of fatty acids. J. clin. Invest. 1960; 39: 717
   PubMed Web of Science ®Google Scholar
• Bianco J. A., Shanahan E. A., Ostheimer G. W., Guyton R. A., Powell W. J., Daggett W. M. Effects of glucagon on myocardial oxygen consumption and potassium balance. Amer. J. Physiol. 1971; 221: 626
   PubMed Web of Science ®Google Scholar
• Carlsten A., Hallgren B., Jagenburg R., Svanborg A., Werkö L. Myocardial metabolism of glucose, lactic acid, amino acids and fatty acids in healthy human individuals at rest and at different work loads. Scand. J. clin. Lab. Invest. 1961; 13: 418
   PubMed Web of Science ®Google Scholar
• Challoner D. R., Steinberg D. Oxidative metabolism of myocardium as influenced by fatty acids and epinephrine. Amer. J. Physiol. 1966; 211: 897
   Web of Science ®Google Scholar
• Diamond G., Forrester J., Danzig R., Parmley W. W., Swan H. J. C. Acute myocardial infarction in man. Comparative hemodynamic effects of norepinephrine and glucagon. Amer. J. Cardiol. 1971; 27: 612
   PubMed Web of Science ®Google Scholar
• Diamond G., Forrester J., Danzig R., Parmley W. W., Swan H. J. C. Hemodynamic effects of glucagon during acute myocardial infarction with left ventricular failure in man. Brit. Heart J. 1971; 33: 290
   PubMedGoogle Scholar
• Dole V. P. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J. clin. Invest. 1956; 35: 150
   PubMed Web of Science ®Google Scholar
• Eddy J. D., O'Brien E. T., Singh S. P. Glucagon and hemodynamics of acute myocardial infarction. Brit. med. J. 1969; 4: 663
   PubMedGoogle Scholar
• Glick G., Parmley W. W., Wechsler A. S., Sonnenblick Glucagon E. H. Its enhancement of cardiac performance in the cat and dog and persistance of its inotropic action despite beta-adrenergic blockade with propranolol. Circulat. Res. 1968; 22: 789
   PubMed Web of Science ®Google Scholar
• Jennings R. B. Early phase of myocardial ischemic injury and infarction. Amer. J. Cardiol. 1969; 24: 753
   PubMed Web of Science ®Google Scholar
• Kjekshus J. K., Maroko P. R., Sobel B. E. Distribution of myocardial injury and its relation to epicardial ST-segment changes after coronary artery occlusion in the dog. Cardiovasc. Res. 1972; 6: 490
   PubMed Web of Science ®Google Scholar
• Kjekshus J. K., Mjös O. D. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J. clin. Invest. 1972; 51: 1767
   PubMed Web of Science ®Google Scholar
• Kjekshus J. K., Mjös O. D. Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion. J. clin. Invest. 1973; 52: 1770
   PubMed Web of Science ®Google Scholar
• Klocke F. J., Kaiser G. A., Ross J., Jr, Braunwald E. Mechanism of increase of myocardial oxygen uptake produced by catecholamines. Amer. J. Physiol. 1965; 209: 913
   PubMed Web of Science ®Google Scholar
• Kumar R., Sharma G. V. R. K., Molokhia F. A., Norman J. C., Inamdar A. N., Messer J. V., Abelmann W. H., Hood W. B. Experimental myocardial infarction. X. Efficacy of glucagon in acute and healing phase in intact conscious dogs: Effects on hemodynamics and myocardial oxygen consumption. Circulation 1972; 45: 55
   PubMed Web of Science ®Google Scholar
• Lucchesi B. R. Cardiac actions of glucagon. Circulat. Res. 1968; 22: 777
   PubMed Web of Science ®Google Scholar
• Manchester J. H., Parmley W. W., Matloff J. M., Leidtke A. J., La Raia P. J., Herman M. V., Sonnenblick E. H., Gorlin R. Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and in dog. Circulation 1970; 41: 579
   PubMed Web of Science ®Google Scholar
• Maroko P. R., Kjekshus J. K., Sobel B. E., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971; 43: 67
   PubMed Web of Science ®Google Scholar
• Marsiglia J. C., Moreyra A. E., Lardani H., Cingolani Glucagon H. E. Its effect upon myocardial oxygen consumption. Europ. J. Pharmacol. 1970; 12: 265
   PubMed Web of Science ®Google Scholar
• Matloff J. K., Parmley W. W., Manchester J. H., Berkovits B., Sonnenblick E. H., Harken D. E. Hemodynamic effects of glucagon and intra-aortic balloon counterpulsation in canine myocardial infarction. Amer. J. Cardiol. 1970; 25: 675
   PubMed Web of Science ®Google Scholar
• Mjös O. D. Effect of isoproterenol, glucagon and calcium on myocardial oxygen consumption in intact dogs. A comparative study. Scand. J. clin. Lab. Invest. 1971; 28: 127
   PubMed Web of Science ®Google Scholar
• Mjös O. D. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J. clin. Invest. 1971; 50: 1386
   PubMed Web of Science ®Google Scholar
• Mjös O. D. Effect of inhibition of lipolysis on myocardial oxygen consumption in the presence of isoproterenol. J. clin. Invest. 1971; 50: 1869
   PubMed Web of Science ®Google Scholar
• Mjös O. D., Kjekshus J. K. Increased local metabolic rate by free fatty acids in the intact dog heart. Scand. J. clin. Lab. Invest. 1971; 28: 389
   PubMed Web of Science ®Google Scholar
• Mjös O. D., Lekven J., Kjekshus J. K. Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J. clin. Invest., submitted for publication
   Web of Science ®Google Scholar
• Polumbo R. A., Leighton R. F., Weissler A. M. Efficacy of isoproterenol-glucagon infusion in patients with heart disease. Circulation 1971; 43: 786
   PubMed Web of Science ®Google Scholar
• Puri P. S., Bing R. J. Effects of glucagon on myocardial contractility and hemodynamics in acute experimental myocardial infarction. Basis for its possible use in cardiogenic shock. Amer. Heart J. 1969; 78: 660
   PubMed Web of Science ®Google Scholar
• Raab W. The nonvascular metabolic myocardial vulnerability factor in ‘coronary heart disease’. Amer. Heart J. 1963; 66: 685
   PubMed Web of Science ®Google Scholar
• Regan T. J., Moschos C. B., Lehan P. H., Oldewurtel H. A., Hellems H. K. Lipid and carbohydrate metabolism of myocardium during the biphasic inotropic response to epinephrine. Circulat. Res. 1966; 19: 307
   PubMed Web of Science ®Google Scholar
• Ribeilima J., Wendt V. E., Ramos H., Gudbjarnason S., Bruce T. A., Bing R. J. The effects of norepinephrine on the hemodynamics and myocardial metabolism of normal human subjects. Amer. Heart J. 1964; 67: 672
   PubMed Web of Science ®Google Scholar
• Rowe G. G. Systemic and coronary hemodynamic effects of glucagon. Amer. J. Cardiol. 1970; 25: 670
   PubMed Web of Science ®Google Scholar
• Scott J. C., Finkelstein L. J., Spitzer J. J. Myocardial removal of free fatty acids under normal and pathological conditions. Amer. J. Physiol. 1962; 203: 482
   PubMed Web of Science ®Google Scholar
• Shubin H., Weil M. H. The treatment of shock complicating acute myocardial infarction. Progr. cardiovasc. Dis. 1967; 10: 30
   PubMedGoogle Scholar
• Snedecor G. W., Cochran W. G. Statistical Methods6th Ed. The Iowa State University Press, Ames 1967
   Google Scholar
• Sokal J. E., Aydin A., Kraus G. Effect of glucagon on plasma free fatty acids of normal and pancreatectomized dogs. Amer. J. Physiol. 1966; 211: 1334
   PubMed Web of Science ®Google Scholar
• Sonnenblick E. H., Ross J., Jr, Braunwald E. Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Amer. J. Cardiol. 1968; 22: 328
   PubMed Web of Science ®Google Scholar
• Spilker B. Comparison of the inotropic response to glucagon, ouabain and noradrenaline. Brit. J. Pharmacol. 1970; 40: 382
   PubMed Web of Science ®Google Scholar
• Trout D. L., Estes E. H., Friedberg S. J. Titration of free fatty acids in plasma: A study of current methods and a new modification. J. Lipid Res. 1960; 1: 199
   PubMed Web of Science ®Google Scholar
• Vander Ark C. R., Reynolds E. W., Jr. Continuous infusion of glucagon in cardiogenic shock. Circulation. 1969; 40: 206, abstr, Suppl.111
   Web of Science ®Google Scholar
• Watanabe T., Covell J. W., Maroko P. R., Braunwald E., Ross J., Jr. Effects of increased arterial pressure and positive inotropic agents on the severity of myocardial ischemia in the acutely depressed heart. Amer. J. Cardiol. 1972; 30: 371
   PubMed Web of Science ®Google Scholar
• Westlie L., Andersen A., Jervell J., Rasmussen K., Storstein O. Cardiovascular effects of glucagon. Acta med. scand. 1971; 189: 179
   PubMedGoogle Scholar
• Wilcken D. E. L., Lvoff R. Glucagon in resistant heart-failure and cardiogenic shock. Lancet 1970; 1: 1315
   Web of Science ®Google Scholar
• Wirsen C. Studies in lipid mobilization. Acta physiol. scand. 1965; 65, Suppl. 252
   Google Scholar